Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast Cancer.

Song, Yan; Hao, Yanni; Macalalad, Alexander R; Lin, Peggy L; Signorovitch, James E; Wu, Eric Q

Song, Yan; Hao, Yanni; Macalalad, Alexander R; Lin, Peggy L; Signorovitch, James E; Wu, Eric Q.

Afiliación

Song Y; Analysis Group, Inc., Boston, MA, USA.
Hao Y; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Macalalad AR; Analysis Group, Inc., Boston, MA, USA.
Lin PL; Analysis Group, Inc., Boston, MA, USA.
Signorovitch JE; Analysis Group, Inc., Boston, MA, USA.
Wu EQ; Analysis Group, Inc., Boston, MA, USA.

Breast Cancer (Auckl) ; 9: 67-72, 2015.

Article en En | MEDLINE | ID: mdl-26380551

Palabras clave

HR+/HER2−metastatic breast cancer; breast cancer; chemotherapy; clinical outcomes; endocrine therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Breast Cancer (Auckl) Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google